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Abstract
Background
Isoflavonoids are of interest owing to their appearance in metabolic pathways of isoflavones, and their estrogenic and other
physiological properties, making them promising lead compounds for drug design.
Results
The reduction of isoflavones by various hydride reagents occurs by a 1,4-pathway in contrast to ordinary β-alkoxy-α,β-unsaturated
ketones. Isoflavan-4-ones, cis- and trans-isoflavan-4-ols, α-methyldeoxybenzoins or 1,2-diphenylprop-2-en-1-ols are obtained
depending on the hydride reagent, mostly in good yields. The stereoselective reduction of isoflavan-4-ones is also discussed.
Conclusion
The work described in this paper shows that most structural types of reduced isoflavonoids are now reliably available in satis-
factory or good yields by hydride reductions to be used as authentic reference compounds in analytical and biological studies.
Background
The reduction of isoflavones 1 has been actively studied during
the last twenty years, owing to the range of interesting biolo-
gical  effects  [1-3]  –  estrogenic  activity,  promise  in  cancer,
osteoporosis, and coronary heart disease prevention – shown by
the isoflavones themselves and their reduced metabolites. There
are  some  reports  [4-8]  of  total  syntheses  of  reduced
isoflavonoid structures from commercially available starting
materials but overall yields in these multistep procedures tend
to be low, and free hydroxy groups are not compatible. Another
strategy  involves  the  hydrogenation  of  isoflavones  using  a
palladium  or  platinum  catalyst  but  mixtures  of  reduction
products are often formed [9,10]. Certain hydride reagents have
been tested, as discussed below, for the reduction of simple or
protected isoflavones but many of the early results are contra-
dictory or rely on indeterminate product characterization.
The reduction of simple (nonflavonoid) β-alkoxy-α,β-unsatur-
ated ketones by hydride reagents (NaBH4,  LiAlH4,  DIBAH)
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Figure 1: Isoflavonoid subclasses.
occurs normally by 1,2-attack, this being a key step in the well
known "carbonyl transposition" of 1,3-diketone enol ethers into
enones (R3O-CR=CR1-COR2 → R-CO-CR1=CHR2). [11-15]
Prior  to our work there were no reports  on the reduction of
isoflavones containing free hydroxy groups which nevertheless
are common, usually at one or several of the C-5, C-7 and C-4'
sites,  in  the  naturally  occurring  isoflavonoids.  It  is  to  be
expected that the presence of the phenolic hydroxyls, or the
derived phenolate anions, will alter the reactivity pattern of the
parent isoflavone system, besides perhaps decreasing the overall
reactivity due to solubility reasons. For example, any tendency
of hydride attack at the C-2 will be opposed by electron feeding
from the 4'-OH group while an OH group at C-5 or C-7 will
discourage attack at C-2 and C-4. Thus there was ample room
for the development of reliable methods for the synthesis of
hydroxy-substituted isoflavone metabolites, and for clarifica-
tion  of  the  course  of  reduction  of  isoflavones  with  various
hydride reducing agents. We present here experimental details
of our own results in this field together with a thorough survey
of the literature. The discussion is based on the types of reduced
isoflavonoid structures formed (Figure 1), i.e., isoflavanones 2,
cis-isoflavan-4-ols 3, trans-isoflavan-4-ols 4, the ring opened
α-methyldeoxybenzoins 5 and 1,2-diaryl-2-propen-1-ols 6, and
isoflavenes 7 and 8 (hydride reductions do not lead to isoflavans
9, which however are obtained by catalytic hydrogenation [10,
16,20]). Incidentally, it is appropriate to point out that flavones
do not undergo similar reductive metabolism in mammals as
described above for isoflavones. We will nevertheless present at
a later date certain findings on the hydride reduction pathways
in flavones.
Results and Discussion
Isoflavanones (2)
Isoflavanones result from the 1,4-reduction of isoflavones. The
resonance contributor 10 will encourage this mode of attack.
DIBAH,  normally  a  preferential  1,2-reducer,  reacts  with
methoxy-,  benzyloxy-,  MOMO-  and  MEMO-substituted
isoflavones  to  give  the  isoflavanones  in  40–93% yield  [16,
21-23] (Table 1). Our own work has shown that even unpro-
tected hydroxy-substituted isoflavones are reduced by a large
excess of DIBAH in 50–70% yield (Table 1). The simple boro-
hydride reagents reduce isoflavones to the isoflavanols (see
below) but the Selectrides® give 60–88% yields of isoflavan-
ones in the absence of hydroxy substituents according to our
results (Table 1). There is no significant difference between the
K-  and  L-Selectride®.  In  the  literature,  there  is  an  isolated
report  of the reduction of a MOM substituted isoflavone by
L-Selectride® in 40% yield (Table 2) [16]. Methoxy substituted
isoflavones  have  also  been  reduced  by  sodium  hydrogen
telluride  to  give  isoflavan-4-ones  in  61–71%  yields  [24].
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Table 1: Reduction of isoflavones to isoflavanones.a
a all R groups = H
b R7 = OMe, other R groups = H
c R4' = R7 = OMe, other R groups = H
d R7 = OH, other R groups = H
e R4' = OMe, R7 = OH, other R groups = H
f R4' = OMe, R5 = R7 = OH, other R groups = H
R2' R3' R4' R5' R6' R5 R6 R7 R8 reductant, eqs yield %
DIBb, 4 72
SELc, 4 96
OH DIB, 10 68
SEL, 8 0
OMe DIB, 2.5 90d,e
DIB, 6 57
SEL, 4 84
Me OMe OMe DIB, 2.5 75e
OMe OMe OMe DIB, 2.5 89e
OMe OMe OMe NaHTe, 2 68f
OH OH DIB, 25 70
SEL, 8 0
OMe OH DIB, 25 60
OMe OMe DIB, 2.5 87e
DIB, 7 54
NaHTe, 2 61f
SEL, 4 82
OMOM OMOM DIB, 4.7 93g
OH OH OH DIB, 25 50
SEL, 9 0
OMe OH OH DIB, 25 57
OMe OMe OMe OMe NaHTe, 2 71f
OMOM OMOM OMOM DIB, 4.7 87g,h
SEL, 2 40g
OMe OMe OBn OBn DIB, 2.5 40i
OBn OMe OMe OMe DIB, 2.5 56e
OBn OBn OMe OMe OMe DIB, 1.9 52j
OBn OBn OBn OMe OMe DIB, 1.9 57j
OBn OBn OMe OMe OMe OBn DIB, 1.9 67j
OBn OMe OMe OMe OBn DIB, 1.9 61j
OBn OBn OBn OMe OMe OBn DIB, 1.9 58j
a Only substituents other than H are shown in the Table. Items without a reference are results reported here for the first time. b DIB = di-isobutylalu-
miniumhydride. c SEL = K- or L-Selectride®. d 2-Methyl-7-methoxyisoflavone reacted similarly in 63% yield.[21] e Ref. 21. f Ref. 24. g Ref. 16. h The
corresponding tris(methoxyethoxymethoxy)flavone reacted similarly. i Ref. 23. j Ref. 22.
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Table 2: Reduction of isoflavones to isoflavan-4-olsa
SM R2 R2' R4' R6 R7 R8 reductant, eqs, solvent yield 3+4 % 3:4 ratio Yld 6 %
1a NaBH4,2.5,EtOH 86 70:30 12
LiBH4,2.5,THF 56 80:20 40
NaBH4,2.5,MeOH 57b 3 only
NaBH4,2,EtOH 75c,d
NaBH4,2,diglyme 88d,e
NaBH4,3.5,PdCl2,aq. THF 85 82:18
NaBH4,H3BO3,2.5, EtOH 98 71:29
NaBH4,CeCl3,1.0, DMSO 99 3 only
NaBH4,AlCl3,excess., digl. 81d
Zn(BH4)2,4,Et2O 69 62:38 19
LiEt3BH,4,THF 50 70:30
B2H6, excess,THF 76c,d
1b OMe NaBH4,2.5,EtOH 90 70:30 9
NaBH4,H3BO3,3.1, EtOH 80f 3 only
NaBH4,H3BO3,2.5, EtOH 97 70:30
NaBH4,CeCl3,1.5, DMSO 88 3 only 12
LiBH4,10,THF 54 70:30 37
LiEt3BH,4,THF 55 65:35
1c OMe OMe NaBH4,2.5,MeOH 37b 3 only
NaBH4,2.5,EtOH 88 70:30 10
NaBH4,CeCl3,2.5, DMSO 86 3 only 10
NaBH4,H3BO3,2.5, EtOH 96 70:30
LiBH4,10,THF 70 77:23 10
Zn(BH4)2,2,Et2O 74 62:38
LiEt3BH,4,THF 36 78:22
1 OMOM OMOM OMOM NaBH4,15.9,EtOH, THF
LiBH4,10,THF
87g
82g
65:35
57:43
1 Me Br OMe NaBH4,4.2,EtOH 25e,h
1 Me Br OBn NaBH4,4.2,EtOH 22e,h
1 Me OMe Br NaBH4,4.2,EtOH 20e,h
1 Me Br OMe Br NaBH4,4.2,EtOH 20e,h
a Only substituents other than H are shown. According to our results, OH substituted isoflavones are not reduced, nor are such reactions reported in
the literature. Items without a reference are results reported here for the first time. b Ref. 25. c Product was given as 2-isoflaven-4-ol. d Ref. 28. e
Product ratio not given. f Ref. 26. g Ref. 16. h Ref. 27.
Isoflavanols (3, 4)
Full reduction at the heterocyclic ring of isoflavones by LiBH4
or NaBH4 leads to isoflavanols in 20–91% yield (Table 2), [16,
25-28]except with hydroxy substituted substrates which do not
react at all. Apparently the first step involves a 1,4-addition to
give the isoflavanone enolate which picks up a proton from the
solvent and is reduced further to the saturated alcohol. There are
no reports of the intermediacy of the alternative 1,2-reduction
products,  the  allylic  alcohols  11  which  in  fact  appear  very
incompletely  known in  the  chemical  literature  (see  below).
Similarly, the reduction of isoflavanones 2 by LiBH4, NaBH4,
L-Selectride®  or Li(t-BuO)3AlH gives mixtures of cis-3  and
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Table 3: Reduction of isoflavanones to isoflavan-4-olsa
SM R2' R3' R4' R7 reductant, eqs, solvent yield 3+4 % 3:4 ratio
2a NaBH4, ng.,EtOH
NaBH4,2,MeOH,THF
Li(t-BuO)3AlH,10,THF
B2H6,80,THF
99b
99c
99c
98c
70:30
42:58
34:66
3 only
2b OMe NaBH4,2,MeOH,THF
NaBH4,1.2,EtOH
Li(t-BuO)3AlH,10,THF
L-Selectride, ng
B2H6,80,THF
BTEDg,0.7,THF
99c
67d
99c
99c
99c
98c
44:56
67:33
33:67
37:63
3 only
3 only
2 OH OH LiBH4,6.9,THF 94e 70:30
2 OTBDMS OTBDMS LiBH4,2,THF 96f 70:30
2c OMe OMe NaBH4,2,THF,MeOH
NaBH4,1.2,EtOH
Li(t-BuO)3AlH,10,THF
B2H6,80,THF
99c
50d
99c
97c
43:57
3 only
34:66
3 only
BTEDg,0.7,THF 97c 3 only
2 OMe OMe OMe NaBH4,2,THF,MeOH 99c 36:64
Li(t-BuO)3AlH,10,THF 99c 32:68
B2H6,80,THF 98c 3 only
BTEDg,0.7,THF 98c 3 only
2 OMOM OMOM OMOM LiBH4,10,THF 73h 55:45
LiAlH4,17,THF 78h 45:55
NaBH4,15.9,THF,MeOH 91h 70:30
a Only substituents other than H are shown. ng not given b Ref. 31. c Ref. 29. d Ref. 30. e Ref. 32. f Ref. 33. g bis-t-butylthioethane diborane. h Ref. 16.
trans-isoflavan-4-ols 4 (Table 3). [16,29,34] Isoflavanones are
reduced by electrophilic hydrides (borane-tetrahydrofuran, bis-
tert-butylthioethane  borane)  diastereoselectively  to  cis-
isoflavan-4-ols,  but  a  large  excess  of  the  reducing  agent  is
usually  needed  [29].
Although it was realized by the early workers that diastereo-
meric mixtures of isoflavanols would presumably be formed,
there were no reliable methods to determine their structures. In
some papers, the products are summarily assigned the cis [25,
26]  or  trans  [35-38]  structures.  However,  rigorous  NMR
analysis  has  recently  made  it  possible  to  establish  cis-  and
trans-structures for the isoflavanol products and to study their
conformational  equilibria  [32,34].  Borohydride  reductions
generally  give  a  small  preference  for  the  cis  products  as
suggested  by  Cram's  rule  [39].  We  are  not  aware  of  any
examples in the literature of single enantiomers of isoflavanone
Figure 2: 2-Isoflaven-4-ols and 1-(2-hydroxyphenyl)-2-phenyl-2-
propen-1-one
or  isoflavanol  metabolites,  nor  have  such  compounds  been
reported as hydride reduction products of isoflavones. In view
of the significant biological properties of the reduced metabol-
ites it will be interesting to examine the behaviour of the pure
enantiomers.
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Table 4: Reduction of isoflavones to α-methyldeoxybenzoins and 1,2-diaryl-2-propen-1-olsa
a all R groups = H
b R7 = Me, other R groups = H
c R4 = R7 = Me, other R groups = H
R2' R4' R5 R7 reductant, eqs, solvent yield (%)
of 5 of 6
LiAlH4, 2.5,THF 27b 48
Li(t-BuO)3AlH, 5,THF 74 6
Red-Al, 2.5,THF 12 50
LiBH4, 10, THF 9 68
OMe LiAlH4, 2.5,THF 29b 50
LiAlH4, 1, THF 62c -
Li(t-BuO)3AlH,10,THF 88 12
LiBH4, 10, THF 7 37
OMe OMe LiAlH4,3.3,THF 27b 70
Li(t-BuO)3AlH,10,THF 88 12
LiBH4, 10, THF 5 10
OH LiAlH4,3.3,THF 60b -
Li(t-BuO)3AlH,8,THF - -
OH OH LiAlH4,5.5,THF 42b -
Li(t-BuO)3AlH,10,THF - -
OMe OH LiAlH4,3.3,THF 42b -
OH OH OH LiAlH4,5.5,THF 66b -
OMe OH OH LiAlH4,4.3,THF 70b -
OH OMe LiAlH4,3.3,THF 17b 34
OMOM OMOM OMOM LiAlH4,7.9,THF 6d -
a Only substituents other than H are shown in the Table. Items without a reference are results reported here for the first time. b Ref. 43. c Ref. 44. d
Ref. 16.
2-Isoflaven-4-ols (11)
There are very few reports of this class of compounds, either
from reductive processes or otherwise. In 1965, the reduction of
the parent isoflavone by NaBH4 in EtOH or diborane in THF
was claimed [28] to furnish 2-isoflaven-4-ol in 75–76% yield,
but unfortunately the characterization of this product relied on
elemental analysis only. More recently, Japanese workers [40]
reported that the reduction of 12 (Figure 2) by NaBH4 in the
presence of PdCl2 in THF-H2O gave a 1:1 mixture of the ketone
13a  and the  diol  13b  (Figure  2).  A 1H NMR spectrum was
given for the latter isoflavenol but there appear to be certain
discrepancies, notably in the δ value (8.69) reported for the H-8
which is some 2 δ units in excess of what would be expected for
such a vinyl ether proton. Thus more work is required to fully
confirm the nature of this class of reduction products. In the
event, in our studies the reduction of isoflavone 1a by NaBH4 in
the presence of PdCl2 in THF-H2O gave a 82:18 mixture of cis-
and trans-isoflavan-4-ol 3a, 4a while no 2-isoflaven-4-ols were
observed. The absence of such 1,2-reduction products, or struc-
tures conceivably derivable thereof such as 2- or 3-isoflavenes
(7, 8), even in the CeCl3-complexed NaBH4 reductions, must
reflect  the  good  stabilization  obtainable  via  resonance
heteroring  stabilization  (10)  in  the  isoflavones.  As  already
mentioned, this is in contrast to the behaviour of simple non-
flavonoid β-alkoxy-α,β-unsaturated ketones which prefer 1,2-
attack by hydride.
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Figure 3: Dietary isoflavones and their metabolites in humans.
e R4’=OMe, R7= OH, other R groups = H
f R4’= OMe, R5=R7= OH, other R groups = H
g R4’= R5=R7= OH, other R groups = H
h R4’=R7= OH, other R groups = H
i R4’=R7= OH, R6=OCH3, other R groups = H
j R4’= R6=R7= OH, other R groups = H
k R3’= R7= OH, other R groups = H
l R3’=R4’=R7= OH, other R groups = H
Isoflavenes (7, 8) and isoflavans (9)
In the early work, [41] there is a mention of 7,4'-dimethoxy-2-
methyl-3-isoflavene  being  obtained  in  15% yield  from the
reduction of the corresponding isoflavone by LiAlH4 in Et2O-
benzene but there is no structural data on the product other than
elemental  analysis,  itself  quite  accurate.  Similarly  2',4'-
dimethoxy-3',6,7-trihydroxyisoflav-3-ene was reported from the
reduction of 2',4'-dimethoxy-3',6,7-trihydroxyisoflavan-4-one
with LiAlH4 in low yield [42]. More recent work by us [43] and
others [16,44] would indicate that the normal course of LiAlH4
reduction of isoflavones leads to deoxybenzoins and propenols
(see below and Table 4).
Published syntheses of 2- and 3-isoflavenes involve the reduc-
tion of 3-arylcoumarins, [45-47] the corresponding aldehyde
hemiacetals, [7] isoflavylium salts [48-50] or of isoflavones by
the Clemmensen reaction [51].  Low-yielding non-reductive
routes to 2- and/or 3-isoflavenes have also been reported [52,
53]. 2-Isoflavenes 7 however remain mostly poorly character-
ized, and some of the NMR spectral details reported [7,51,52]
appear inconsistent with the 2-isoflavenoid structure. As far as
the NMR spectra of 2-isoflavenes are concerned, a recent study
clears this issue by 2D NMR work on a natural 2-isoflavene,
[54] establishing that the H-2 and H-4 protons appear at δ 6.87
and 3.61, respectively, much as expected by correlation data
shift  calculations.  Isoflavans (9)  have not  been prepared by
hydride  reductions,  but  by  catalytic  hydrogenation  of
isoflavones  [10,16-20].
Deoxybenzoins (5) and propenols (6)
Isoflavanones undergo a facile retro-Michael-type ring opening
[21,55] under basic conditions to give the propenone interme-
diate 14 (Figure 2), sometimes considered [56] to be an inde-
pendent isoflavone metabolite but presumably just an artefact in
reality. As regards the synthesis of isoflavanones by DIBAH
reduction of isoflavones (see above), we found that unless the
workup is done with cold methanolic HCl, some amount of the
propenone 14 will be formed and reduced further to the deoxy-
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benzoin 5. If on the other hand the deoxybenzoins are the actual
synthetic  targets,  the reducing agent  of  choice is  LiAlH4  in
THF. This works very well for isoflavones bearing a hydroxy
group at  C-7 such as genistein,  but  in isoflavones lacking a
7-OH group another reaction pathway competes leading to the
propenols 6 [43] as byproducts (see below). We have discussed
a  possible  mechanism to  explain  these  hydroxyl-dependent
divergent  pathways  [43].
To summarize, all hydride addition reactions with isoflavones
appear to involve an initial 1,4-addition to give the isoflavanone
enolate. In a hydroxylic solvent, or even on workup under basic
conditions, the ketone is generated, and reduced further to the
saturated  alcohol  (NaBH4).  In  a  nonprotic  solvent,  the
β-aryloxyenolate will undergo a retro-Michael addition, giving
the phenolate anion of the ring opened 2-propen-1-one which
may undergo a 1,2- or 1,4-addition of hydride (LiAlH4, LiBH4).
If the O-metal bond in the initial enolate is very tight, the ring
opening  does  not  occur  and  allows  the  isolation  of  the
isoflavanone (DIBAH, Selectrides®). The presence and number
of hydroxy or alkoxy substituents in the substrates does not
have a major effect in these reductions except in the case of
NaBH4  reduction which fails completely presumably due to
solubility reasons, and the LiAlH4 reduction where the outcome
depends on the presence or absence of an OH group at C-7.
Based on our and previous results by other workers, the redu-
cing agents of choice for the synthesis of reduced isoflavonoids
are as follows:
isoflavanones (2) from non-hydroxylated isoflavones DIBAH or
Selectrides®
isoflavanones (2) from hydroxylated isoflavones DIBAH
cis-isoflavanols (3) from non-hydroxylated isoflavones NaBH4/
CeCl3
cis-isoflavanols  (3)  from hydroxylated isoflavones no good
methods
cis-isoflavanols (3) from non-hydroxylated isoflavanones B2H6
or BTED
trans-isoflavanols (4) from isoflavones no good methods
trans-isoflavanols (4) from isoflavanones Li(t-BuO)3AlH
2-isoflaven-4-ols (11) from isoflavones uncertain
isoflavenes (7, 8) from isoflavones Clemmensen
isoflavans (9) from isoflavones H2, Pd/BaSO4
α-methyldeoxybenzoins (5) from non-hydroxylated isoflavones
Li(t-BuO)3AlH
α-methyldeoxybenzoins  (5)  from hydroxylated  isoflavones
LiAlH4
1,2-diaryl-2-propen-1-ols  (6)  from  non-hydroxylated
isoflavones  LiBH4  or  LiAlH4
Conclusion
Dietary  isoflavonoids  in  vegetables,  beans,  peas  and  other
legumes are possible cancer preventing agents, particularly in
hormone  based  cancers  such  as  breast  and  prostate  cancer.
[57-59] Epidemiological studies have shown that they decrease
the  risk  of  colon  cancer,  osteoporosis,  and  coronary  heart
disease. [1-3] Significantly, health claims of soy foods, rich in
isoflavonoids, have recently received FDA authorization [60].
The dietary isoflavonoids are mainly metabolized in man via
reductive  pathways,  leading to  the  reduced structural  types
discussed above (Figure 3). These compounds are often more
estrogenic than the starting isoflavones. Research interest in
many fields including medicine, nutrition and biosynthesis and
metabolism thus converge on the reduced isoflavonoids. The
work described in this paper shows that most structural types of
reduced isoflavonoids are now reliably available in satisfactory
or good yields by hydride reductions. Although not discussed
here, it is clear that D atoms may be introduced in the same way
which is very useful in the quantitation of the naturally occur-
ring compounds by GC-MS selected ion monitoring techniques
[61].
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